FDA Says Ranbaxy Falsified Data From India Plant
The agency said Wednesday it has halted its review of any new or pending drug approval applications with data generated from the Ranbaxy plant in Paonto Sahib and asked the facility to submit a correction action plan to address concerns with integrity of its data.
The action relates only to the Paonto Sahib facility. It applies...
Already a subscriber? Click here to login